{ }
Very Negative
Negative
Neutral
Positive
Very Positive
2025-03-302025-03-301111100
Download SVG
Download PNG
Download CSV
Somewhat Relevant
Moderately Relevant
Very Relevant
Highly Relevant
2025-03-302025-03-301111100
Download SVG
Download PNG
Download CSV

AI in healthcare faces regulatory hurdles but shows strong investment potential

Artificial intelligence is set to revolutionize healthcare, with Barclays projecting a growth rate exceeding 30% annually through 2030. However, regulatory hurdles and uncertain reimbursement policies may hinder widespread adoption. Key players include UnitedHealth Group and Thermo Fisher Scientific, alongside high-risk firms like Tempus and Recursion Pharmaceuticals, as the industry navigates challenges in trust and implementation costs.

saudi public investment fund ranks second in global sovereign investment activity

Saudi Arabia’s Public Investment Fund (PIF) ranked as the world’s second most active sovereign investor in February, committing $3 billion across three overseas deals. This surge reflects a strategic shift towards global opportunities, with PIF managing $925 billion in assets and focusing on sectors like healthcare and gaming. Notable moves include increased stakes in Lucid Motors and Amazon, alongside a $3.5 billion acquisition of Niantic’s gaming division.

cell line development market projected to grow at 12.13 percent CAGR through 2031

The global Cell Line Development Market is projected to grow at a CAGR of 12.13% from 2024 to 2031, driven by increasing demand in drug discovery and biopharmaceutical production. Key players include Lonza Group AG, Thermo Fisher Scientific Inc, and GE Healthcare, with significant regional markets in North America, Europe, and Asia-Pacific. The report offers insights into market trends, challenges, and opportunities, utilizing both qualitative and quantitative research methods.

deutsche bank lowers price target for thermo fisher scientific to 615

Deutsche Bank has adjusted its price target for Thermo Fisher Scientific to $615 from $630 while maintaining a Buy rating. The company specializes in laboratory and scientific equipment, with net sales primarily from laboratory equipment (73.9%), followed by scientific analysis equipment (16.3%) and diagnostics products (9.8%). Geographically, sales are led by North America (53.1%), followed by Europe (25.1%) and Asia/Pacific (18.4%).

thermo fisher scientific sees insider selling and institutional investment shifts

Thermo Fisher Scientific experienced an 8.25% decrease in insider ownership, with executives selling 29,000 shares worth $15.86 million in the last three months. Institutional investors hold 89.23% of the stock, with State Street Corp and FMR LLC increasing their stakes significantly. UBS Group raised its price target for the stock to $715, indicating a potential upside of 19.23%.

lateral flow assay market analysis trends and growth opportunities 2024 to 2031

Priya Pandey, a biotechnology graduate, excels in creating engaging content across various industries, including healthcare and technology. Coherent Market Insights offers comprehensive market intelligence and consulting services, providing detailed reports on sectors like food and beverages and pharmaceuticals, with insights into market dynamics and competitive strategies. The latest report on the Lateral Flow Assay Market forecasts trends and growth from 2024 to 2031, analyzing consumer behavior and regulatory factors while highlighting key players and emerging opportunities.

growth opportunities in the tuberculosis diagnostics market through 2033

The global tuberculosis diagnostics market, valued at approximately $2.05 billion in 2023, is projected to grow to $3.6 billion by 2033, driven by advancements in nucleic acid testing and increasing healthcare investments. Key opportunities lie in smear microscopy, active tuberculosis detection, and hospital diagnostics, with significant growth expected in the Asia-Pacific and North America regions. Major players include Beckton, Dickinson and Company, Qiagen, and F. Hoffmann-La Roche, collectively holding a substantial market share.

global clinical biomarkers market projected to reach 47 billion by 2031

The global clinical biomarkers market, valued at $25.02 billion in 2023, is projected to reach $47.25 billion by 2031, growing at a CAGR of 8.54%. This growth is driven by rising cancer cases and advancements in diagnostic technologies, despite challenges like high costs and reimbursement issues. Key players include Roche, Abbott, and Johnson & Johnson, with significant developments in biomarker testing for various diseases.

global growth trends in the crispr and cas gene market to 2033

The global CRISPR and Cas gene market reached approximately $3.3 billion in 2023, growing at a CAGR of 20.38% since 2018. It is projected to expand to $8.8 billion by 2028 and $24.6 billion by 2033, driven by advancements in cancer therapeutics and gene therapy research. North America leads the market, accounting for 45.3% of the total value in 2023.

disaster and emergency medicine market poised for significant growth and innovation

The Disaster and Emergency Medicine Market is set for significant growth, driven by technological advancements and strategic collaborations among key players. Comprehensive research, including primary interviews and secondary literature reviews, has validated insights into the current market landscape. Prominent companies like Baxter International, Halyard Health, and 3M Healthcare are pivotal in shaping trends and enhancing emergency response capabilities.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.